Rallybio/RLYB
$1.80
-1.64%-
1D1W1MYTD1YMAX
About Rallybio
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Ticker
RLYB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Martin Mackay
Employees
43
Headquarters
New haven, United States
Website
rallybio.com
Rallybio Metrics
BasicAdvanced
$76M
Market cap
-
P/E ratio
-$1.88
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$76M
52-week high
$9.14
52-week low
$1.23
Average daily volume
1.6M
Financial strength
Current ratio
9.77
Management effectiveness
Return on assets (TTM)
-58.3%
Return on equity (TTM)
-62.43%
Return on investment (TTM)
-62.32%
Valuation
Price to book
0.776
Price to tangible book (TTM)
0.851
Growth
Earnings per share change (TTM)
8.63%
What the Analysts think about Rallybio
Analyst Ratings
Majority rating from 6 analysts.
Price Targets
Average projection from 4 analysts.
High $20.00
Low $8.00
$1.80
Current price
$13.00
Average price target
Rallybio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$19M
-5.94%
Profit margin
0%
NaN%
Rallybio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.46
-$0.45
-$0.50
-$0.47
-
Expected
-$0.48
-$0.51
-$0.45
-$0.47
-$0.41
Surprise
-3.74%
-11.52%
11.23%
-0.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $76M as of May 14, 2024.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of May 14, 2024.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of May 14, 2024.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) does not currently have a Beta indicator.
What is the Rallybio stock price target?
The target price for Rallybio (RLYB) stock is $13, which is 630.34% above the current price of $1.78. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Rallybio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.